PET Imaging of Peptide Probe Al[<sup>18</sup>F]F-NOTA-PCP1 for Monitoring the Engagement of PD-L1 Antibodies in Tumors-Reference-Cited by-同舟云学术

PET Imaging of Peptide Probe Al[¹⁸F]F-NOTA-PCP1 for Monitoring the Engagement of PD-L1 Antibodies in Tumors

Published:2024-01-30 Issue: Volume: Page:
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Zhang Yang¹,Wang Yong¹,Chen Yunhao²,Ding Xingchen¹,Wang Shijie³,Liu Wei¹,Hu Man⁴¹^ORCID,Liu Zhiguo⁵

Affiliation:

1. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, Shandong China

2. Department of Oncology, Shandong Provincial Third Hospital. Jinan 250031, Shandong, China

3. Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, Jinan 250117, Shandong, China

4. Department of Radiation Oncology, Shandong University Cancer Center, Jinan 250117, Shandong, China

5. College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, China

Funder

National Natural Science Foundation of China

Natural Science Foundation of Shandong Province

Jinan Science and Technology Bureau

Shandong provincial colleges and universities youth innovation technology support program

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.3c01151

Reference37 articles.

1. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

2. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation

3. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

4. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

5. Blocking PD-L1–PD-1 improves senescence surveillance and ageing phenotypes